Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02611089

Muscle Connective Tissue in Limb Development and Disease

The objective of this work is to understand how the disruption of the muscle connective tissue contributes to the limb soft-tissue defects in radial dysplasia. In parallel, the researchers will investigate the role of muscle connective tissue in normal limb development.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Sex eligibility

All sexes

Study type

Observational

Primary location

Oxford University Hospitals, Oxford, Oxfordshire, United Kingdom

Loading trial locations.

About this study

The objective of this work is to understand the origins of the soft tissue defects in a disabling, disfiguring limb anomaly called radial dysplasia, and what mechanisms of normal limb development have been disrupted in these patients to produce their phenotype. The investigators aim to use this knowledge to improve their treatment. Currently, despite sophisticated surgical treatment, the limb malformation the child is born with typically recurs as they grow: it is thus an 'unsolved problem'.

The investigators have previously shown, in an experimental mouse model of radial dysplasia, the underlying soft tissue problem is a change in the muscle connective tissue and its derivatives, causing abnormal soft-tissue patterning. The investigators wish to expand this work into the investigators' patient population by comparing samples of post-natal muscle connective tissue derivatives from radial dysplasia patients with control samples.

The investigators will ask patients undergoing corrective hand surgery to let the investigators take small tissue samples during their planned operations. The investigators will also ask patients having other forms of hand surgery, such as surgery for hand injuries, to let the investigators take similar samples for comparison. In either case, their scar and peri-operative treatment will be unchanged. The investigators will examine the tissue samples in the investigators' laboratory to look for changes in tissue architecture, cellular composition, cell signalling, and how they behave when grown in culture. The investigators will also make attempts to derive cell lines from biopsy samples to use in further studies, exploring cellular phenotype and functional capacity.

Simultaneously, the investigators will look at the long-term surgical outcomes and the range of genetic changes in the investigators' patient population. Eligible patients will be referred for consideration in the (separate) 100,000 genome project; this should further expand the investigators' knowledge of the genetic changes underlying limb anomalies. The ability to combine data on genotype, long-term phenotype and soft tissue changes will give a comprehensive overview of the condition. The investigators expect this to lead to a better understanding of patient subgroups, and to provide a rational basis for improved treatment approaches.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Cases

Inclusion criteria

  • Patients with a clinical diagnosis of radial dysplasia, requiring reconstructive surgery
  • Either sex
  • Informed (parental) consent to participate

Exclusion criteria

  • Patients with a clinical diagnosis of radial dysplasia, but not requiring reconstructive surgery
  • Patients with a diagnosis other than radial dysplasia
  • Patients with extensive previous scarring to their forearm and hand.
  • Patients with a significant pathological skin or soft tissue lesion at the donor site.

Controls

Inclusion criteria

  • Patients with an injury requiring reconstructive surgery
  • Either sex
  • Informed (parental) consent to participate

Exclusion criteria

  • Patients with extensive previous scarring to their forearm and hand.
  • Patients with a significant pathological skin or soft tissue lesion at the donor site.

Treatment and study plan

Tissue biopsy

Procedure

Sampling of tissue as described.

Primary outcomes

  1. Characterisation of muscle connective tissue derivatives - structure

    Time frame: 3 years

    The characterization of any structural difference in tissue organisation within muscle connective tissue derivatives, comparing normal control patients to patients with radial dysplasia.

  2. Characterisation of muscle connective tissue derivatives - function

    Time frame: 3 years

    The characterization of any functional difference in gene expression within muscle connective tissue derivatives, comparing normal control patients to patients with radial dysplasia.

Secondary outcomes

  1. Identification of biomarker(s).

    Time frame: 3 years

    The identification of a novel biomarker (or biomarkers) for human muscle connective tissue derivatives, which may potentially serve as a diagnostic or prognostic tool

  2. Identification of muscle connective tissue progenitor-cell pool.

    Time frame: 3 years

    The potential identification of a stem-cell-like or progenitor-cell pool for muscle connective tissue derivatives in mature soft tissue.

Study contacts

Contact information is provided by the study sponsor or research team.

George Murphy, PhD FRCS

CONTACT

[email protected]

Malcolm Logan, BSc PhD

CONTACT

[email protected]

02078486886

Sponsors and collaborators

Lead sponsor

King's College London

Other

Collaborators

  • Chelsea and Westminster NHS Foundation Trust
  • Great Ormond Street Hospital for Children NHS Foundation Trust
  • Royal Free Hospital NHS Foundation Trust

Registry information

Important dates

Study start
2016
Primary completion
2026
Study completion
2036
First posted
Nov 20, 2015
Registry last updated
Aug 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.